Lexicon Pharmaceuticals (LXRX) Gross Profit (2016 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Gross Profit data on file, last reported at $21.0 million in Q1 2026.

• On a quarterly basis, Gross Profit rose 1604.06% year-over-year to $21.0 million in Q1 2026; TTM through Mar 2026 was $69.3 million, a 126.46% increase from a year earlier, with the FY2025 full-year figure at $49.5 million, up 62.58% from the prior year.
• Gross Profit for Q1 2026 stood at $21.0 million, up from $5.3 million in the prior quarter.
• Over the last five years, Gross Profit for LXRX reached as high as $28.8 million in Q2 2025 and fell as low as $35000.0 in Q2 2022.
• Historically, Gross Profit has averaged $7.9 million across 5 years, with a median of $1.5 million in 2024.
• Across the five-year window, Gross Profit jumped 3665.23% in 2024 and slumped 79.81% in 2025, its largest moves.
• Year by year, Gross Profit stood at $35000.0 in 2022, then jumped by 1888.57% to $696000.0 in 2023, then soared by 3665.23% to $26.2 million in 2024, then slumped by 79.81% to $5.3 million in 2025, then jumped by 296.71% to $21.0 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $21.0 million in Q1 2026, $5.3 million in Q4 2025, and $14.2 million in Q3 2025.